Quality Assurance for Carotid Stenting in the CREST-2 Registry Article

Full Text via DOI: 10.1016/j.jacc.2019.10.032 PMID: 31856962 Web of Science: 000503035600001

Cited authors

  • Lal, Brajesh K.; Roubin, Gary S.; Rosenfield, Kenneth; Heck, Donald; Jones, Michael; Jankowitz, Brian; Jovin, Tudor; Chaturvedi, Seemant; Dabus, Guilherme; White, Christopher J.; Gray, William; Matsumura, Jon; Katzen, Barry T.; Hopkins, L. Nelson; Mayorga-Carlin, Minerva; Sorkin, John D.; Howard, George; Meschia, James F.; Brott, Thomas G.

Abstract

  • BACKGROUND The CREST-2 Registry (C2R) was approved by National Institute of Neurological Disorders and Stroke-National Institutes of Health in September 2014 with Centers for Medicare & Medicaid Services, U.S. Food and Drug Administration, and industry collaboration to enroll patients undergoing CAS. The registry credentials interventionists and promotes optimal patient selection, procedural-technique, and outcomes.; OBJECTIVES This study reports periprocedural outcomes in a cohort of carotid artery stenting (CAS) performed for asymptomatic and symptomatic carotid stenosis.; METHODS Asymptomatic patients with >= 70% and symptomatic patients with >= 50% carotid stenosis, <= 80 years of age, and at standard or high risk for carotid endarterectomy are eligible for enrollment. Interventionists are credentialed by a multispecialty committee that reviews experience, lesion selection, technique, and outcomes. The primary endpoint was a composite of stroke and death (S/D) in the 30-day periprocedural period. Myocardial infarction and access-site complications were assessed as secondary outcomes.; RESULTS As of December 2018, 187 interventionists from 98 sites in the United States performed 2,219 CAS procedures in 2,141 patients with primary atherosclerosis (78 were bilateral). The mean age of the cohort was 68 years, 65% were male, and 92% were white; 1,180 (55%) were for asymptomatic disease, and 961 (45%) were for symptomatic disease. All U.S. Food and Drug Administration-approved stents and embolic protection devices were represented. The 30-day rate of S/D was 1.4% for asymptomatic, 2.8% for symptomatic, and 2.0% for all patients.; CONCLUSIONS C2R is the first national registry for CAS cosponsored by federal and industry partners. CAS was performed by experienced operators using appropriate patient selection and optimal technique. In that setting, a broad group of interventionists achieved very low periprocedural S/D rates for asymptomatic and symptomatic patients. (C) 2019 by the American College of Cardiology Foundation.

Authors

Publication date

  • 2019

Published in

International Standard Serial Number (ISSN)

  • 0735-1097

Start page

  • 3071

End page

  • 3079

Volume

  • 74

Issue

  • 25